Alzheimer's Drug Discovery Foundation

Agenda

Thursday, April 9, 2015	
9:00–9:25	**Breakfast**
9:25–10:15	**Introductory Session**
9:25–9:45	**The Biology of Comparative Effectiveness and the Aging Brain** Howard Fillit, MD—Alzheimer's Drug Discovery Foundation
9:45-10:15	**The Causes and Consequences of Geriatric Cognitive Decline** Anand Viswanathan, MD, PhD—Massachusetts General Hospital; American Heart Association Representative
10:15–10:45	**Value and Challenges of Cost-Effectiveness and Comparative Effectiveness Research** Peter Neumann, ScD—Tufts Medical Center
10:45–12:15	**Session 1: Case Studies of the Relationship between Drugs to Manage Common Chronic Conditions and the Risk of Dementia and/or Mild Cognitive Impairment**
10:45–11:15	**Diabetes Drugs and the Risk of Mild Cognitive Impairment and Dementia** Lenore Launer, PhD, MSc—National Institutes of Health
11:15–11:45	**Anti-Hypertensive Medications and the Risk of Mild Cognitive Impairment and Dementia** Rachel Whitmer, PhD—Kaiser Permanente
11:45–12:15	**Cardiovascular Disease Management and the Risk of MCI and Dementia** Lewis Kuller, MD—University of Pittsburgh
12:15-1:00	**Lunch**
1:00–3:30	**Session 2: Perspectives on Potential Evidentiary Standards for the Risk of Dementia and/or Mild Cognitive Impairment to Influence Clinical Management of Common Chronic Conditions with Available Drugs**
1:00–1:30	**The FDA Perspective** Allan Green, MD, PhD, JD—Allan M. Green, MD, PhD, JD, LLC
1:30–2:00	**The Payer Perspective** Richard Stefanacci, DO, MGH, MBA, AGSF, CMD—Thomas Jefferson University
2:00–2:30	**Evidentiary Standards to Influence Clinical Practice Guidelines for Diabetes** Sue Kirkman, MD—University of North Carolina School of Medicine; American Diabetes Association Representative
2:30-2:45	**Break**
2:45–3:00	**Evidentiary Standards to Influence Clinical Practice Guidelines for Hypertension** Lawrence Krakoff, MD—Mount Sinai Hospital
3:00–3:30	**The Role of the Patient Perspective in CER** Lori Frank, PhD—Patient-Centered Outcomes Research Institute (PCORI)
3:30–4:15	**Panel Discussion**

Alzheimer's Drug Discovery Foundation

Friday, April 10, 2015	
8:00am–8:30	**Breakfast**
8:30–10:00	**Session 3: Needs and Opportunities to Strengthen the Evidence**
8:30–9:00	**Comorbid Populations and the Need to Study Real-World Populations** Joshua Armstrong, PhD—Dalhousie University
9:00–9:30	**The Pharma Perspective on Studying Dementia Risk or Mild Cognitive Impairment in Relation to Drugs on the Market or in Development for Other Chronic Conditions** Stephen Brannan, MD—Takeda Pharmaceuticals
9:30–10:00	**Adding Cognitive Outcomes to Randomized Controlled Trials** Jeff Williamson, MD—Wake Forest Baptist Medical Center
10:00–10:15	**Break**
10:15–11:15	**Session 3 (cont.)**
10:15–10:45	**Observational Study Designs for Comparative Effectiveness** Priscilla Velentgas, MS, PhD—Quintiles
10:45–11:15	**Electronic Health Records, Patient Databases, and Data Linkage Opportunities** Simon Lovestone, PhD, MRCPsych— University of Oxford
11:15-1:15	**Panel Discussion: Are There Specific Studies to be Done at this Time?**
11:15–11:45	**Hypertension Medications**
11:45–12:15	**Hyperlipidemia Medications**
12:15–12:45	**Lunch**
12:45–1:15	**Diabetes Medications**
1:15–2:15	**Final Discussion and Concluding Remarks**
2:15	**Adjourn**